Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care. CancerNetwork® spoke with Dirk Schadendorf, MD, professor of dermatology and oncology and director of the Department of Dermatology and the…